AdvisorShares Psychedelics ETF (PSIL) Stock Analysis

AdvisorShares Psychedelics ETF (PSIL) Financial Services Profile

AdvisorShares Psychedelics ETF (PSIL) is a non-diversified, actively managed fund targeting the burgeoning psychedelic medicine industry. It invests in companies deriving significant revenue or assets from psychedelic drugs and derivatives, offering investors exposure to this specialized and evolving sector with a beta of 0.38.

What Is the Investment Thesis for PSIL?

The AdvisorShares Psychedelics ETF (PSIL) presents a focused investment opportunity within the emerging psychedelic medicine market. The core thesis rests on the anticipated growth of this sector, driven by increasing acceptance of psychedelic-assisted therapies for mental health conditions. Key value drivers include regulatory advancements, clinical trial successes, and the commercialization of novel psychedelic drugs. The fund's actively managed approach allows for strategic allocation to companies poised to benefit from these trends. However, potential risks include regulatory setbacks, competition from traditional pharmaceutical companies, and the inherent volatility associated with early-stage biotech and pharmaceutical ventures. With a beta of 0.38, PSIL exhibits lower volatility compared to the broader market, but the concentrated nature of the fund amplifies sector-specific risks. The absence of a dividend yield reflects the fund's focus on capital appreciation rather than income generation.

Based on FMP financials and quantitative analysis

PSIL Key Highlights

Market Cap of $26.3M indicates a relatively small fund size, suggesting potential for higher growth but also greater volatility.

• Beta of 0.38 suggests the fund is less volatile than the overall market.
• Actively managed structure allows for strategic adjustments to the portfolio based on developments in the psychedelics industry.
• Non-diversified nature concentrates risk and reward within the psychedelics sector.
• Focus on companies deriving at least 50% of revenue or assets from psychedelics provides targeted exposure to the industry.

Who Are PSIL's Competitors?

PSIL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PSIL's Key Strengths?

First mover advantage in the psychedelics ETF market.

• Actively managed portfolio allows for strategic adjustments.
• Provides targeted exposure to a high-growth sector.
• Low beta suggests lower volatility compared to the broader market.

What Are PSIL's Weaknesses?

Non-diversified nature concentrates risk.

• Small market cap may limit liquidity.
• Dependent on the regulatory and social acceptance of psychedelics.
• High expense ratio compared to broader market ETFs.

What Could Drive PSIL Stock Higher?

Clinical trial results for psychedelic-assisted therapies expected in 2026-2027.

• Increasing media coverage and public awareness of psychedelics.
• Regulatory advancements and policy changes regarding psychedelic treatments.

What Are the Key Risks for PSIL?

Regulatory setbacks or delays in approvals for psychedelic therapies.

• Negative publicity or safety concerns regarding psychedelics.
• Competition from traditional pharmaceutical companies with established mental health treatments.
• Market volatility and economic downturns impacting investor sentiment.

What Are the Growth Opportunities for PSIL?

• Regulatory Approvals: The potential for regulatory approvals of psychedelic-assisted therapies represents a significant growth catalyst for PSIL. As governments and regulatory bodies like the FDA consider the therapeutic benefits of psychedelics for conditions such as depression and PTSD, companies within the ETF's portfolio could experience substantial growth. The timeline for potential approvals varies, but advancements in clinical trials and shifting public perception could accelerate the process, potentially leading to increased investment and market expansion by 2028.
• Clinical Trial Successes: Positive results from clinical trials evaluating the efficacy of psychedelic drugs for various mental health conditions could drive significant growth for companies held within PSIL. Successful trials would validate the therapeutic potential of psychedelics, attracting further investment and paving the way for commercialization. The ongoing clinical trials are expected to yield results over the next 2-3 years, with potential market impact by 2027. The market size for mental health treatments is substantial, offering significant upside for successful psychedelic therapies.
• Increased Investment in Research and Development: Growing awareness of the potential benefits of psychedelics is driving increased investment in research and development within the sector. This influx of capital could fuel innovation and accelerate the development of novel psychedelic drugs and therapies, benefiting companies held within PSIL. The market for psychedelic R&D is projected to grow significantly over the next 5 years, reaching billions of dollars by 2030, creating opportunities for companies to expand their pipelines and market presence.
• Shifting Societal Attitudes: Changing societal attitudes towards mental health and alternative therapies are creating a more favorable environment for the acceptance and adoption of psychedelic treatments. As stigma surrounding mental health diminishes and more people seek out innovative solutions, the demand for psychedelic therapies is likely to increase, driving growth for companies within PSIL. This shift in attitudes is an ongoing process, but increasing media coverage and advocacy efforts are contributing to greater awareness and acceptance, potentially leading to broader adoption by 2028.
• Expansion of Treatment Centers and Clinics: The establishment and expansion of specialized treatment centers and clinics offering psychedelic-assisted therapies will be crucial for the widespread adoption of these treatments. As regulatory hurdles are cleared and more therapies become available, the demand for qualified treatment providers will increase, creating opportunities for companies within PSIL to partner with or invest in these facilities. The market for psychedelic treatment centers is expected to grow rapidly over the next decade, with potential for significant expansion by 2030, driving revenue growth for companies involved in the provision of psychedelic therapies.

What Are PSIL's Competitive Advantages?

• First-mover advantage in offering a dedicated psychedelics ETF.
• Expertise in actively managing a portfolio of companies within the psychedelics sector.
• Brand recognition as a leading provider of specialized ETFs.

What Does PSIL Do?

AdvisorShares Psychedelics ETF (PSIL) is an actively managed exchange-traded fund launched with the specific objective of providing investors exposure to the emerging psychedelics industry. The fund strategically invests at least 80% of its net assets, plus any borrowings for investment purposes, in companies that derive at least 50% of their net revenue from, or devote 50% of their assets to, psychedelic drugs and derivatives. This focus encompasses publicly listed life sciences companies actively engaged in the research, development, and production of psychedelic medicines, as well as other companies involved in the broader psychedelics business. The ETF's investment strategy is centered on identifying and capitalizing on the growth potential within the psychedelics sector, which is driven by increasing scientific research, regulatory changes, and shifting societal attitudes toward mental health treatments. By concentrating its investments in this niche market, PSIL offers investors a targeted approach to participate in the potential upside of the psychedelics industry. However, it is important to note that the fund is non-diversified, meaning its performance is closely tied to the performance of a relatively small number of holdings, which can amplify both gains and losses. As of 2026, the fund maintains a market capitalization of $26.3M.

What Products and Services Does PSIL Offer?

• Invests in companies deriving revenue from psychedelic drugs and derivatives.
• Focuses on publicly listed life sciences companies in the psychedelic medicine space.
• Actively manages a portfolio of securities within the psychedelics business.
• Seeks capital appreciation through investments in the psychedelics sector.
• Provides investors with exposure to the emerging market for psychedelic medicines.
• Targets companies that devote a significant portion of their assets to psychedelic drugs.

How Does PSIL Make Money?

• Actively manages a portfolio of stocks focused on the psychedelics industry.
• Generates revenue through management fees charged to investors.
• Aims to provide capital appreciation for investors by investing in companies involved in psychedelic drugs and derivatives.

What Industry Does PSIL Operate In?

The AdvisorShares Psychedelics ETF (PSIL) operates within the rapidly evolving psychedelics industry, which is gaining traction as a potential solution for mental health disorders. The market is characterized by increasing research into the therapeutic benefits of substances like psilocybin and MDMA, coupled with regulatory changes that could pave the way for legal medical use. PSIL competes with other specialized ETFs and investment vehicles focused on the cannabis and biotech sectors, but its exclusive focus on psychedelics differentiates it. The competitive landscape includes companies developing novel psychedelic drugs, as well as those providing support services such as clinical research and therapy.

Who Are PSIL's Key Customers?

• Institutional investors seeking exposure to the psychedelics industry.
• Retail investors interested in investing in the emerging market for psychedelic medicines.
• Financial advisors looking for specialized investment products for their clients.

How AdvisorShares Psychedelics ETF Is Valued

AdvisorShares Psychedelics ETF carries a market capitalization of $26.3M, placing it in the micro-cap category.

Return on equity for AdvisorShares Psychedelics ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. PSIL trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

PSIL Financials

PSIL Latest News

No recent news available for PSIL.

PSIL Analyst Consensus

PSIL MoonshotScore

Common Questions About PSIL (Financial Services)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources